The evolution of treatment resistance: biologic implications

Area of Science:

• Psychiatry
• Neuroscience
• Pharmacology

Background:

• Treatment resistance in schizophrenia is a significant clinical challenge.
• Positive, negative, and cognitive symptoms of schizophrenia may exhibit different resistance patterns to antipsychotic therapy.
• Understanding these patterns could aid in subtyping schizophrenia and identifying distinct etiologies.

Purpose of the Study:

• To investigate the evolution of antipsychotic resistance in schizophrenia.
• To compare treatment resistance patterns between positive and negative symptoms.
• To evaluate clozapine's efficacy in patients with varying degrees of treatment resistance.

Main Methods:

• Analysis of data from 223 patients with unsatisfactory responses to standard antipsychotic therapy.
• Comparison of treatment outcomes between subgroups with primary and delayed onset treatment resistance.
• Assessment of clozapine response and the impact of clozapine withdrawal on treatment resistance.

Main Results:

• Resistance of positive symptoms to antipsychotics may evolve over time, unlike negative symptoms and cognitive deficits.
• Approximately 60% of patients with unsatisfactory responses to classical antipsychotics responded to clozapine.
• Patients with delayed treatment resistance showed a better response to clozapine than those with primary resistance.
• Clozapine withdrawal could induce treatment resistance in previously responsive patients.

Conclusions:

• The differential evolution of resistance suggests distinct pathophysiological mechanisms for positive versus negative/cognitive symptoms in schizophrenia.
• Clozapine is an effective treatment for various forms of antipsychotic resistance in schizophrenia.
• Treatment resistance patterns may inform schizophrenia subtyping and guide therapeutic strategies.